Price movement over the last 24 hours
Align Technology, Inc. vs JPMorgan Equity Premium Income ETF — how do they compare? Align Technology, Inc. trades at $179.45 (market cap $12.86B), while JPMorgan Equity Premium Income ETF trades at $56.77. The key difference: Align Technology, Inc. is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| ALGN | JEPI | |
|---|---|---|
Market Cap | $12.86B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $207.19 | $59.88 |
52-Week Low | $124.88 | $55.29 |
Enterprise Value | $11.92B | — |
Signals from Pluang's Aura AI — not financial advice
Align Technology (ALGN) trades at $179.45, up 0.72% with a bullish technical outlook from moving averages. The company maintains solid profitability with a 10.5% net margin and has beaten EPS estimates for three consecutive quarters. Recent developments include a new manufacturing facility in India and upcoming Q2 2026 earnings on July 29, 2026.
ALGN offers growth potential with a consensus price target of $218.40, representing 22% upside, supported by 73% analyst buy ratings. Risks include European regulatory scrutiny and North American demand pressures. The stock's valuation at 30x P/E requires sustained earnings growth to justify further gains.
JEPI trades at $56.76, up 0.23% with a bullish technical signal from moving averages. The ETF's covered-call strategy generates an 8%+ yield but caps upside potential during bull markets. Recent news highlights JEPI's appeal for income-focused investors seeking monthly distributions with lower volatility than the S&P 500.
JEPI offers high income through option premiums but faces total return limitations in rising markets. The fund's active management provides drawdown resilience, though tax efficiency concerns exist compared to alternatives. Current market conditions favor income strategies, but investors should weigh yield against growth constraints.
Trailing returns across standard periods
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →